Holdings in Company and PDMR Shareholding

January 04, 2017

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each (“Ordinary Shares”) respectively, at an average price of 5.74 pence per Ordinary Share (the “Transaction”).

Launch of New Website

December 19, 2016

Proteome Sciences is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company’s interim results statement of 14 September 2016.

Result of General Meeting and Completion of Placing

November 29, 2016

Proteome Sciences plc (AIM:PRM) is pleased to announce that at its General Meeting held earlier today, all resolutions were duly passed.

Smart Capture Phases for Proteomics, Glycomics & Biomarker Assays

November 01, 2016

Proteome Sciences partners with the BioCapture Network in this interdisciplinary project we will design high affinity responsive molecular capture materials targeting tumor specific markers. Molecularly imprinted polymers or “plastic antibodies” and other smart materials will be developed and used to detect and sense previously inaccessible tumor markers or to discover novel disease biomarkers. 

Placing & Subscription of 66,258,100 Shares & General Meeting Notice

October 31, 2016

Notice of a General Meeting of Proteome Sciences Plc, to be held at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ at 10 a.m. on 29 November 2016.

Investigating of Phospho-Tau Forms as Alzheimer's Markers

October 07, 2016"The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease."

Block Admission Return

October 03, 2016
Proteome Sciences Block Admission Return.

Spectrometry Technique Enhances Detection of Early Stage AD Biomarkers

September 22, 2016

“This study clearly demonstrates the potential of combined tissue and fluid proteomics to discover and validate low abundant, tissue-derived biomarkers in peripheral fluids, which in this case resulted in the widest coverage of both tau and phosphorylated tau in human cerebrospinal fluid.

Stacking the Odds in Alzheimer's Disease Drug Development

September 20, 2016

We have been developing several drugs that modulate the phosphorylation of the aggregating protein tau in Alzheimer’s disease by inhibiting the protein casein kinase 1 delta. We have tested them in a model of human tauopathy (aggregating tau diseases) and analyzed brain tissue with SysQuant® to determine the drug’s mechanism of action.

Proteome Sciences Interim Results

September 15, 2016
“We are pleased to report that performance during the first six months of 2016 has been in line with expectations, and it is encouraging that revenues remain well ahead of the equivalent period in 2015